Lorena Signati

This paper develops a nanoplatform using red blood cell-derived extracellular vesicles to deliver Cetuximab and cisplatin, enhancing cancer cell killing and reducing toxicity in triple-negative breast cancer.

This paper introduces an enhanced SiMoA platform using membrane sensing peptides to detect HER2 on extracellular vesicles in metastatic breast cancer patients, showing improved sensitivity and prognostic relevance.

This study uses Raman spectroscopy to analyze biochemical changes in circulating extracellular vesicles between breast cancer patients and healthy controls, identifying distinct signatures of nucleic acids and lipids in cancer samples.